GSTM1 and chronic kidney disease: Notably, in the first phase 2 study conducted in China, Hb response in CKD patients with NDD-CKD was dose-dependent and significantly higher in the roxadustat arms than in the placebo arm (88.5% and 93.1% of the low- and high-dose cohorts, respectively, versus in 25.9% of placebo subjects; P < 0.0001) (Chen et al., 2017).